Navigation Links
Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
Date:4/15/2008

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that results from the company's Phase 2a clinical trial evaluating PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), will be presented as a late-breaking clinical trial at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition in New Orleans, May 14-17, 2008.

PS433540 is being developed as a potential treatment for both hypertension and diabetic nephropathy and is the first and only blood pressure product candidate in development that possesses two validated mechanisms of action in a single compound.

Joel Neutel, MD, lead investigator and Director of Research, Orange County Research Center, Tustin, Calif., will present results of the Phase 2a clinical trial. In addition to the late-breaker, Pharmacopeia will also present data from its Phase 1 Multiple Ascending Dose (MAD) Study of PS433540.

Late-breaker presentation:

-- "A Double Blind, Placebo Controlled Study to Evaluate the Safety and

Efficacy of a Novel New Dual Acting Receptor Antagonist (DARA

Compound) in Human Subjects with Hypertension"

-- Friday, May 16, 2008, 5:38 - 5:55 p.m. CDT (6:38 - 6:55 p.m. EDT)

-- New Orleans Marriott, Acadia Ballroom, 3rd Floor

Poster presentation:

-- "PS433540 a Novel Dual Acting Receptor Antagonist Dose Dependently

Increases Plasma Renin Activity in Healthy Volunteers"

-- Abstract # P-14

-- Wednesday, May 14, 2008, Posters on Display: 3:00 - 7:00 p.m. CDT

(4:00 - 8:00 p.m. EDT), Poster Discuss
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
2. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
3. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
4. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
5. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015 BGI a annoncé aujourd,hui que ... l,ADN situé à Hong Kong ... of Pathologists  (Collège des pathologistes américains, ou CAP). ... Kong constituent le premier laboratoire clinique ... certification du CAP en Chine, car il satisfait ...
(Date:7/2/2015)... , July 2, 2015  New product launches ... its leading role in educating thought leaders about new ... can heavily influence how well a new therapy performs ... study from research and consulting leader Best Practices, LLC, ... need to focus on are early stage thought leader ...
(Date:7/2/2015)... YORK , July 2, 2015 ... a conspicuously high-growth market segment in hematology testing, ... publisher said that Roche,s recent unveiling of its Bloodhound ... the cobas m 511 hematology analyzer ... only capture growth enjoyed by current leader CellaVision, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
(Date:7/3/2015)... Lewisville, TX (PRWEB) , ... July 03, 2015 , ... ... in the United States, named Mariah N. Manzanares, MD as the new Medical Director ... the new facility medical director of our Frisco facility,” said Dr. James M. Muzzarelli, ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is ... opening is the first sweetFrog store located in Mississippi. The premium frozen yogurt chain ... 2014. , The store, located at 104 Railroad Avenue, New Albany, MS 38652, will ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking ... the University of Minnesota, they knew it would save the university energy and ... award-winning choice: the total energy savings after installation was an impressive 89 percent, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... As Americans celebrate ... the hot temps, skin cancer is on the rise. July is UV Safety Month, ... raising awareness about the importance of getting skin checks. Experts say most skin cancers ...
(Date:7/2/2015)... ... July 02, 2015 , ... ActiveBunch.com recently launched as a social network ... to function as a lifestyle community, Active Bunch allows users to connect with like-minded ... and participate in discussions or group events. , The spokesperson for Active Bunch ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... Jan. 12 Just because you are traveling or,on holiday ... good health habits.,In fact, it is an easier time to ... ) , Many Americans take to ... -- be it business or pleasure, and they often fall ...
... developers summit for companies interested in integrating NurseTesting ... ... (Vocus) January 12, 2009 -- Analysts and industry-watchers believe ... but also the entire nature of the business models that ...
... Medical Equipment the 17th fastest growing business in Louisville, Business First ... , ... (Vocus) January 12, 2009 -- DRE, Inc., a premier international ... of Louisville as a 2008 Company of the Year. The award caps ...
... open enrollment helps Medicare recipients make sure they,ve made the ... ... (Vocus) January 12, 2009 -- Although annual Medicare enrollment has ... during the current Medicare open enrollment period. That information comes ...
... Sweden The Swedish investment,company Karolinska Development AB has ... stem cell and other tissue engineering based,treatments for veterinary ... 2007 EvoStem Finland Oy introduced its first product TendoStem(R),which ... and ligament injuries,in horses. TendoStem(R) is currently on the ...
... Inc., a drug development company focusing on serious Central ... that it held an initial closing of $2.9 million ... will use the funds for the clinical development of ... slowing down disease progression and improving memory and cognition ...
Cached Medicine News:Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 3Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 4Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 2Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 3Health News:Business First Selects DRE Medical Equipment as a Company of the Year 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 2Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 4Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 5Health News:Karolinska Development Invests in EvoStem Finland Oy 2Health News:New Venture Funding for Alzheimer's Disease Drug Developer 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: